World Journal of Gastroenterology,
Год журнала:
2024,
Номер
31(3)
Опубликована: Дек. 17, 2024
This
article
discusses
the
recent
study
written
by
Koizumi
et
al.
Alcohol-associated
liver
disease
(ALD)
is
a
major
cause
of
liver-related
morbidity
and
mortality,
which
driven
complex
mechanisms,
including
lipid
accumulation,
apoptosis,
inflammatory
responses
exacerbated
gut
barrier
dysfunction.
The
explored
therapeutic
potential
elafibranor,
dual
peroxisome
proliferator-activated
receptor
alpha/delta
agonist.
In
clinical
trials,
elafibranor
has
shown
promise
for
treatment
other
conditions;
however,
its
effects
on
ALD
remain
unclear.
authors'
findings
indicate
that
significantly
reduced
fibrosis
enhanced
integrity
in
patients
with
ALD.
These
positive
are
mediated
through
multiple
pathways.
Elafibranor
promotes
metabolism,
reduces
oxidative
stress,
inhibits
restoring
function.
Specifically,
it
improves
hepatocyte
function
enhancing
autophagic
antioxidant
capacity,
mitigates
inflammation
suppressing
lipopolysaccharide/toll-like
4/nuclear
factor
kappa
B
signaling
pathway.
promising
applications.
addition,
highlights
elafibranor's
as
agent
diseases,
particularly
underscores
importance
understanding
mechanistic
pathways
underlying
suggests
directions
future
research
aimed
at
elucidating
benefits
limitations
elafibranor.
Frontiers in Microbiology,
Год журнала:
2024,
Номер
15
Опубликована: Ноя. 18, 2024
Background
Alcohol
use
disorder
(AUD)
is
a
psychiatric
that
widespread
worldwide.
significant
contributor
to
the
global
burden
of
death,
disability
and
disease.
Modulation
gut
microbiota
promising
approach
improve
efficacy
minimize
adverse
effects
colorectal
cancer
treatment.
The
relationship
between
presence
microbes
AUD
has
been
widely
validated.
However,
few
studies
have
examined
this
using
bibliometric
methods.
Therefore,
study
analyzes
research
hotspots
trends
in
human
microbiology
over
last
two
decades
from
perspective.
This
aims
at
provide
new
directions
for
basic
clinical
field.
Objective
A
comprehensive
discussion
current
state
intestinal
flora.
Methods
We
collected
publications
Web
Science
Core
Collection
database
2003
2023
according
established
inclusion
criteria.
analyzed
countries,
institutions,
authors,
contributions
CiteSpace,
VOSviewer,
Scimago
Graphics
visualize
Results
total
2,102
were
obtained,
with
rapid
increase
number
since
2016.
United
States
China
are
major
contributors
field
network
partners
several
countries.
Five
hundred
ninety-five
academic
journals
published
articles
on
topic.
author
highest
Prof.
Bernd
Schnabl
Department
Gastroenterology
University
California,
San
Diego.
In
addition
“gut
flora”
“AUD,”
high
frequency
words
keyword
co-occurrence
analysis
included
alcoholic
liver
disease,
tryptophan
metabolism,
enterohepatic
axis,
fecal
microbial
transplantation.
Conclusion
results
visualization
key
areas
past
20
years.
suggest
role
its
potential
mechanisms,
especially
therapeutic
targets,
should
be
closely
monitored
could
become
hot
topic
Frontiers in Pharmacology,
Год журнала:
2024,
Номер
15
Опубликована: Ноя. 28, 2024
Alcohol-related
liver
disease
(ALD)
is
a
major
cause
of
morbidity
and
mortality
worldwide.
It
encompasses
conditions
such
as
fatty
liver,
alcoholic
hepatitis,
chronic
hepatitis
with
fibrosis
or
cirrhosis,
hepatocellular
carcinoma.
Numerous
recent
studies
have
demonstrated
the
critical
role
oxidative
stress,
abnormal
lipid
metabolism,
endoplasmic
reticulum
various
forms
cell
death
(including
apoptosis,
necroptosis,
ferroptosis),
intestinal
microbiota
dysbiosis,
immune
response,
autophagy,
epigenetic
abnormalities
in
pathogenesis
ALD.
Currently,
abstinence,
corticosteroids,
nutritional
therapy
are
traditional
therapeutic
interventions
for
Emerging
therapies
ALD
mainly
include
blockade
inflammatory
pathways,
promotion
regeneration,
restoration
normal
microbiota.
Summarizing
advances
animal
models
will
facilitate
more
systematic
investigation
exploration
targets.
This
review
summarizes
latest
insight
into
molecular
mechanisms
ALD,
well
pros
cons
rodent
models,
providing
basis
further
research
on
strategies
World Journal of Gastroenterology,
Год журнала:
2024,
Номер
31(3)
Опубликована: Дек. 17, 2024
This
article
discusses
the
recent
study
written
by
Koizumi
et
al.
Alcohol-associated
liver
disease
(ALD)
is
a
major
cause
of
liver-related
morbidity
and
mortality,
which
driven
complex
mechanisms,
including
lipid
accumulation,
apoptosis,
inflammatory
responses
exacerbated
gut
barrier
dysfunction.
The
explored
therapeutic
potential
elafibranor,
dual
peroxisome
proliferator-activated
receptor
alpha/delta
agonist.
In
clinical
trials,
elafibranor
has
shown
promise
for
treatment
other
conditions;
however,
its
effects
on
ALD
remain
unclear.
authors'
findings
indicate
that
significantly
reduced
fibrosis
enhanced
integrity
in
patients
with
ALD.
These
positive
are
mediated
through
multiple
pathways.
Elafibranor
promotes
metabolism,
reduces
oxidative
stress,
inhibits
restoring
function.
Specifically,
it
improves
hepatocyte
function
enhancing
autophagic
antioxidant
capacity,
mitigates
inflammation
suppressing
lipopolysaccharide/toll-like
4/nuclear
factor
kappa
B
signaling
pathway.
promising
applications.
addition,
highlights
elafibranor's
as
agent
diseases,
particularly
underscores
importance
understanding
mechanistic
pathways
underlying
suggests
directions
future
research
aimed
at
elucidating
benefits
limitations
elafibranor.
